Our consulting services primarily support pharmaceutical asset development teams, operating as a “plug and play” companion diagnostic group helping to optimize commercial planning for successful launch of personalized medicines.
Our focus is on helping these asset development teams create comprehensive commercial plans –– designed to drive optimal adoption of companion and other diagnostic tests.
Our work and standardized approach to personalized medicine development ensures that teams consider and address the impact of decisions in all key functional areas – such as technology, regulatory, partners, market access and labs among others – while at the same time ensuring resources are optimally apportioned and allocated.
Unlike a standard consulting model, we do not create comprehensive plans for our clients. Rather, we ensure client buy-in by facilitating teams to make their own decisions and to create their own comprehensive plans, while we roll up our sleeves and work alongside them.
To learn more about the services we offer click here
Accelerated change can only be achieved when a fit-for-purpose change management approach, and enhanced personalized medicine analytical and implementation solution, combine to help pharmaceutical asset development teams fully realize the potential of personalized medicine.
Diaceutics has transformed over six years of research - and a library of over 100 qualitative case studies, 200 quantitative data sets and 60 personalized medicine specific decision tools - into a sophisticated and robust web enabled software application with an easy to understand and navigate user interface.
This application - called Diaceutics Fusion™ - is specifically designed to educate pharmaceutical development teams and facilitate decisions on the approximately 250 additional workstreams required to co-develop and successfully commercialize a companion or other diagnostic alongside a therapy - resulting in the creation of comprehensive and actionable commercial plans.
Learn more about Diaceutics Fusion ™ by clicking here
The personalized medicine space is a rapidly growing and evolving field with seemingly revolutionary announcements, research and developments happening on a daily basis. Keeping track of those changes, and being able to contextualize them to your teams’ individual asset or the implications for your company’s competitive advantage, can be a full time job.
There is not yet one central clearinghouse for personalized medicine news, which is why Diaceutics tracks daily references to personalized medicine on a variety of search engines and analyzes the content to identify patterns and distinguish lasting trends from passing phenomena. We also track biomarker work in clinical trials, maintain a database of diagnostic entrants and the details of their deals, keep a close eye on the rapidly evolving regulatory landscape and monitor SEC and other filings of companies in the space.
All of this highly specific content is combined with our deep experience in pharmaceutical and diagnostic development and launch to provide our clients with the analysis, insights and trends they require to stay abreast of this evolving space – whether they need broad insights across the industry or a narrow focus on their disease area.
Learn more by clicking here
